AL
AKBA icon

Airain Ltd’s Akebia Therapeutics AKBA Stock Holding History

Airain Ltd’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12,628
Closed -$114K – 634
2016
Q1 		$114K Buy
+12,628
New +$102K 0.01% 726
2015
Q3 		– Sell
-19,480
Closed -$200K – 827
2015
Q2 		$200K Buy
+19,480
New +$166K 0.01% 757

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Airain Ltd's AKBA Position: Q2 2016 in Review

Airain Ltd sold out of Akebia Therapeutics (AKBA) in Q2 2016, closing a stake of 12,628 shares — an estimated $114K sold.

Airain Ltd first reported a position in AKBA in Q2 2015 and held it in 2 quarters. The position peaked at $200K in Q2 2015. 93 funds tracked by Wall St. Rank hold AKBA as of Q2 2016.

  • Airain Ltd reported no remaining Akebia Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Airain Ltd sold 12,628 Akebia Therapeutics shares in Q2 2016, an estimated $114K.
  • Airain Ltd first reported a position in Akebia Therapeutics in Q2 2015 and held it in 2 quarters.
  • Airain Ltd's Akebia Therapeutics position peaked at $200K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2016.

Based on Airain Ltd's 13F filing for Q2 2016, filed 5 Aug 2016.